HomeCompareFRLN vs PLD

FRLN vs PLD: Dividend Comparison 2026

FRLN yields 30.82% · PLD yields 3.18%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PLD wins by $6.37M in total portfolio value· pulled ahead in Year 7
10 years
FRLN
FRLN
● Live price
30.82%
Share price
$6.49
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$138.7K
Annual income
$18,790.33
Full FRLN calculator →
PLD
PLD
● Live price
3.18%
Share price
$128.78
Annual div
$4.10
5Y div CAGR
74.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$6.50M
Annual income
$5,256,436.18
Full PLD calculator →

Portfolio growth — FRLN vs PLD

📍 PLD pulled ahead of the other in Year 7

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodFRLNPLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, FRLN + PLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
FRLN pays
PLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

FRLN
Annual income on $10K today (after 15% tax)
$2,619.41/yr
After 10yr DRIP, annual income (after tax)
$15,971.78/yr
PLD
Annual income on $10K today (after 15% tax)
$270.62/yr
After 10yr DRIP, annual income (after tax)
$4,467,970.75/yr
At 15% tax rate, PLD beats the other by $4,451,998.97/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of FRLN + PLD for your $10,000?

FRLN: 50%PLD: 50%
100% PLD50/50100% FRLN
Portfolio after 10yr
$3.32M
Annual income
$2,637,613.25/yr
Blended yield
79.41%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PLD right now

FRLN
Analyst Ratings
2
Buy
5
Hold
Consensus: Hold
Altman Z
-16.9
Piotroski
2/9
PLD
Analyst Ratings
25
Buy
16
Hold
1
Sell
Consensus: Buy
Price Target
$136.00
+5.6% upside vs current
Range: $119.00 — $155.00
Altman Z
1.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

FRLN buys
0
PLD buys
0
No recent congressional trades found for FRLN or PLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricFRLNPLD
Forward yield30.82%3.18%
Annual dividend / share$2.00$4.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%74.4%
Portfolio after 10y$138.7K$6.50M
Annual income after 10y$18,790.33$5,256,436.18
Total dividends collected$95.7K$6.37M
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusHoldBuy

Year-by-year: FRLN vs PLD ($10,000, DRIP)

YearFRLN PortfolioFRLN Income/yrPLD PortfolioPLD Income/yrGap
1$13,782$3,081.66$11,255$555.24+$2.5KFRLN
2$18,716$3,969.20$13,062$1,018.59+$5.7KFRLN
3$25,063$5,037.57$15,903$1,926.67+$9.2KFRLN
4$33,122$6,304.80$20,839$3,823.32+$12.3KFRLN
5$43,228$7,787.05$30,464$8,166.08+$12.8KFRLN
6$55,752$9,498.01$52,054$19,457.30+$3.7KFRLN
7← crossover$71,103$11,448.37$109,886$54,188.93$38.8KPLD
8$89,726$13,645.43$304,030$186,451.18$214.3KPLD
9$112,099$16,092.82$1,166,125$840,813.32$1.05MPLD
10$138,737$18,790.33$6,504,190$5,256,436.18$6.37MPLD

FRLN vs PLD: Complete Analysis 2026

FRLNStock

Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its advanced product candidate is verbrinacogene setparvovec (FLT180a), a gene therapy product candidate that is in Phase 1/2 clinical trials in adult males for the treatment of hemophilia B. The company's products also include FLT190, which is in Phase 1/2 clinical trial for the treatment of Fabry disease; and FLT201, a liver-directed gene therapy product candidate to treat type 1 Gaucher disease and is under Phase 1/2 clinical trial. In addition, it has research programs in various indications for systemic gene therapy. The company was founded in 2015 and is headquartered in Stevenage, the United Kingdom.

Full FRLN Calculator →

PLDREIT

Prologis, Inc. is the global leader in logistics real estate with a focus on high-barrier, high-growth markets. As of December 31, 2020, the company owned or had investments in, on a wholly owned basis or through co-investment ventures, properties and development projects expected to total approximately 984 million square feet (91 million square meters) in 19 countries. Prologis leases modern logistics facilities to a diverse base of approximately 5,500 customers principally across two major categories: business-to-business and retail/online fulfillment.

Full PLD Calculator →
📬

Get this FRLN vs PLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

FRLN vs SCHDFRLN vs JEPIFRLN vs OFRLN vs KOFRLN vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.